- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05877963
Studie för att utvärdera bibehållande av effektivitet vid övergång från anti-kluster av differentierade 20 (CD20) terapi till Ublituximab (ENHANCE)
Utvärdering av bibehållande av effektivitet vid övergång från anti-CD20-terapi till Ublituximab
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: TG Therapeutics Clinical Support Team
- Telefonnummer: 1-877-575-8489
- E-post: clinicalsupport@tgtxinc.com
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35209
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Cullman, Alabama, Förenta staterna, 35058
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
California
-
Orange, California, Förenta staterna, 92697
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Colorado
-
Fort Collins, Colorado, Förenta staterna, 80528
- Rekrytering
- TG Investigational Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20007
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30309
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Atlanta, Georgia, Förenta staterna, 30322
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Savannah, Georgia, Förenta staterna, 31406
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46256
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Kansas
-
Overland Park, Kansas, Förenta staterna, 66212
- Avslutad
- TG Therapeutics Investigational Trial Site
-
Overland Park, Kansas, Förenta staterna, 66205
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Maryland
-
Lutherville, Maryland, Förenta staterna, 21093
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 70809
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Boston, Massachusetts, Förenta staterna, 00002
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Foxborough, Massachusetts, Förenta staterna, 02035
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
North Worcester, Massachusetts, Förenta staterna, 01655
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Wellesley, Massachusetts, Förenta staterna, 02481
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Michigan
-
Farmington, Michigan, Förenta staterna, 48334
- Rekrytering
- TG Investigational Site
-
-
Minnesota
-
Golden Valley, Minnesota, Förenta staterna, 55422
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Plymouth, Minnesota, Förenta staterna, 55446
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63131
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
New York
-
New York, New York, Förenta staterna, 10025
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
New York, New York, Förenta staterna, 11021
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28204
- Rekrytering
- TG Therapeutics Investigational Trial SiteCharlotte
-
Raleigh, North Carolina, Förenta staterna, 27607
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45212
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Cleveland, Ohio, Förenta staterna, 44195
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Dayton, Ohio, Förenta staterna, 45417
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
South Carolina
-
Greenville, South Carolina, Förenta staterna, 29605
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37922
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Avslutad
- TG Therapeutics Investigational Trial Site
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84103
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Virginia
-
Vienna, Virginia, Förenta staterna, 22182
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Washington
-
Kirkland, Washington, Förenta staterna, 98034
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Seattle, Washington, Förenta staterna, 98109
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Spokane, Washington, Förenta staterna, 99208
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Bydgoszcz, Polen, 85-796
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Katowice, Polen, 40-555
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Kielce, Polen, 25-726
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Krakow, Polen, 31-826
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Lodz, Polen, 90-324
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Olsztyn, Polen, 10-561
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Poznan, Polen, 61-583
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Warsaw, Polen, 04-141
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Zabrze, Polen
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
Żory, Polen, 44-240
- Rekrytering
- TG Therapeutics Investigational Trial Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Diagnosis of RMS (2017 Revised McDonald criteria).
-
Participants must meet one of the following prior treatment definitions:
- Participants naïve to treatment.
- Participants previously treated with a disease modifying therapy (DMT) who have discontinued treatment prior to consent and meet the washout requirements.
-
Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.
-
Neurologically stable for > 30 days prior to first dose of ublituximab.
-
Female participants of childbearing potential must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 6 months after the last dose of ublituximab.
-
Part C: participants currently treated with an anti-CD20 agent for at least 6 months and meet the washout requirements prior to W1D1.
-
Part C: Discontinuation of current anti-CD20 must be due to suboptimal experience
Exclusion Criteria:
- History of any serious 3 Infusion Related Reaction (IRR) on prior anti-CD20 therapy.
- Primary-progressive multiple sclerosis (PPMS) or inactive Secondary Progressive MS (SPMS).
- Active chronic (or stable but treated with immune therapy) disease of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).
- Current evidence or known history of clinically significant infection, including: chronic, recurrent, or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment such as, but not limited to chronic urinary tract infection, chronic pulmonary infection with bronchiectasis, tuberculosis, or active hepatitis C virus (HCV).
- Previous serious opportunistic or atypical infection.
- Evidence of chronic active or history of hepatitis B virus (HBV) infection as evidenced by a detectable hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb), or chronic hepatitis C infection. Participants with positive hepatitis C virus antibody (HCV Ab) are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
- History or evidence (clinical, radiological, or biomarker) of suspected or confirmed progressive multifocal leukoencephalopathy (PML).
- Receipt of any live or live-attenuated vaccines (including vaccines for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration.
- Participants requiring treatment with intravenous immune globulin (IVIG) for decreased immunoglobulins within the 12 months prior to W1D1.
- Any active malignancies other than adequately treated basal, squamous cell or in situ carcinoma.
- Participants who have ever received ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab (including for non-MS indications).
Note: Other Inclusion/Exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part A: Ublituximab
Participants will receive a modified regimen of ublituximab including infusions on Day 1 of Week 1 (W1D1), Day 15, if applicable, and ublituximab 450 milligrams (mg) infusion at Week 24. With Protocol Version 6.0, enrollment in Part A was closed. |
Administered as an intravenous (IV) infusion.
Andra namn:
|
|
Experimentell: Part B: Ublituximab /Placebo (Treatment Arm A)
Participants will receive 600 mg of ublituximab on W1D1 followed by a placebo infusion on Day 15 and 450 mg ublituximab infusion at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
IV infusion Administered as an intravenous (IV) infusion.
Andra namn:
|
|
Experimentell: Part B: Ublituximab (Treatment Arm B)
Participants will receive 150 mg of ublituximab on W1D1 followed by 450 mg on Day 15 and at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
Administered as an intravenous (IV) infusion.
Andra namn:
|
|
Experimentell: Part C: Ublituximab (Treatment Arm C)
Participants will receive 150 mg of ublituximab on W1D1, followed by 450 mg on Day 15 and at Week 24. |
Administered as an intravenous (IV) infusion.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Del B: Area under the kurvan under de första 16 veckorna (AUC0-V16) av ublituximab
Tidsram: Före dos och vid flera tidpunkter upp till vecka 16
|
Före dos och vid flera tidpunkter upp till vecka 16
|
|
|
Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48
Tidsram: Baseline up to Week 48
|
The Gd-enhancing T1 lesions will be evaluated using magnetic resonance imaging (MRI) technique. |
Baseline up to Week 48
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Parts A: Percentage of Participants Free of T1 Gd-Enhancing Lesions
Tidsram: Week 48
|
The Gd-enhancing T1 lesions will be evaluated using MRI technique. |
Week 48
|
|
Parts A and B: Percentage of Participants Experiencing Infusion Related Reactions (IRRs)
Tidsram: Up to Week 48
|
IRRs are defined as infusion related adverse events (AEs) that occur within one day of an infusion and resolve within 7 days. IRRs will be reported by investigator. |
Up to Week 48
|
|
Parts A: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores
Tidsram: Part A: Baseline, Week 24 and Week 48
|
The TSQM-9 is a 9-item questionnaire with 3 domains: Satisfaction, convenience, and effectiveness. |
Part A: Baseline, Week 24 and Week 48
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TG1101-RMS401
- 2024-519284-18-00 (Annan identifierare: EU CT Number)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .